Patrick Trucchio, an analyst from H.C. Wainwright, reiterated the Buy rating on Immunocore Holdings. The associated price target remains the same with $100.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Patrick Trucchio has given his Buy rating due to a combination of factors that highlight Immunocore Holdings’ strong performance and potential for future growth. The company reported impressive third-quarter 2025 net product revenue, driven by the continued success of KIMMTRAK, particularly in the U.S. and Europe. KIMMTRAK’s role as the standard of care for metastatic uveal melanoma and its expansion into new markets underscore its robust commercial potential.
Additionally, Immunocore’s strategic advancements in clinical trials, such as the dose selection for brenetafusp in a key Phase 3 trial, demonstrate significant progress in their oncology pipeline. The company’s strong financial position, with substantial liquidity, further supports its ability to execute on its growth strategies. Overall, these elements collectively reinforce Trucchio’s confidence in Immunocore’s leadership in the bispecific T cell receptor space and justify the Buy rating with a $100 price target.
In another report released today, Oppenheimer also maintained a Buy rating on the stock with a $86.00 price target.